Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The companyâs lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naĂŻve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Pointâs kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. Source
No articles found.
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
Organovo is a biotech platform company that has developed a leadership position wi...
Organovo is a biotech platform company that has...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology compa...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a...
Natureâs Sunshine Products (NASDAQ:NATR), a leading natural health and wellness ...
Natureâs Sunshine Products (NASDAQ:NATR), a l...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Join the National Investor Network and get the latest information with your interests in mind.